Novartis Multi-Asset Launch Wave Tests CMC and Supply Chain Limits

Novartis is navigating simultaneous regulatory milestones across immunology, renal, and neuromuscular portfolios that will place compounding demands on its CMC teams and supply chain infrastructure through the remainder of 2026. The Q1 period saw FDA approval of Cosentyx for pediatric hidradenitis suppurativa, an FDA priority review granted to Fabhalta for traditional approval in IgAN, and FDA Breakthrough Therapy designation plus priority review for ianalumab in Sjogren's disease -- each carrying distinct formulation, sterility assurance, and process validation requirements that must be managed in parallel.

The completed acquisition of Avidity adds three late-stage neuromuscular assets to the portfolio, expanding the xRNA platform manufacturing obligations at a time when Novartis has already flagged continued investment in gene and cell therapy, radioligand therapy, and xRNA as emerging technology priorities. Plant heads and supply chain leads will need to assess whether existing capacity and validated processes can absorb the Avidity pipeline without compromising ongoing commercial supply for high-growth brands. Kisqali grew 55% in constant currencies, Pluvicto 70%, Scemblix 79%, and Leqvio 69% in Q1 2026 versus the prior-year quarter -- volume trajectories that carry direct implications for batch scheduling and raw material qualification.

Regulatory submissions for post-marketing requirements (PMR) for Cosentyx were also noted in Q1, signaling that QA and regulatory affairs teams face not only new-product workloads but ongoing commitments to existing approval conditions. Remibrutinib received a positive CHMP opinion for chronic spontaneous urticaria and generated positive Phase III data in chronic inducible urticaria, with Phase II data also reported in food allergy -- a pipeline breadth that Novartis describes as "pipeline-in-a-pill potential" and that will require scalable manufacturing strategies ahead of potential additional submissions.

On the financial side, net sales declined 1% in USD terms to USD 13.1 billion in Q1 2026, with core operating income down 12% in USD to USD 4.9 billion, reflecting US generic erosion and higher R&D investment. Free cash flow was USD 3.3 billion. Full-year 2026 guidance was reaffirmed, with net sales expected to grow low single-digit and core operating income expected to decline low single-digit. Novartis reported these results in an ad hoc announcement published April 28, 2026, via GlobeNewswire.